XML 23 R16.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Stock-based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2024
Share-based Payment Arrangement [Abstract] |
Stock-based Compensation | 8. Stock-based Compensation 2006 Equity Incentive Plan and Amendment to 2006 Plan Private CalciMedica adopted an equity incentive plan in 2006 (“2006 Plan”) that provides for the issuance of common stock to employees, non-employee directors and consultants. Recipients of incentive stock options are eligible to purchase common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2006 Plan provides for the grant of incentive stock options, non-statutory stock options and stock purchase rights. The maximum contractual term of options granted under the 2006 Plan is ten years. The options generally vest 25% on the first anniversary of the grant date, with the balance vesting ratably over the following 36 months. Pursuant to the Merger Agreement, CalciMedica, Inc. assumed the 2006 Plan and all stock options issued and outstanding under the 2006 Plan. 2023 Equity Incentive Plan The Company adopted 2023 Equity Incentive Plan (the “2023 Plan”), which became effective at the closing of the Merger. As of the effective date of the Merger, there were 1,000,000 shares of the Company’s common stock available for grant under the 2023 Plan. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 Plan of up to 5% of shares of the Company’s common stock outstanding (or a lesser number determined by the Company’s board of directors). As of March 31, 2024, 218,576 options have been returned and are unavailable for future grant. Effective January 1, 2024, the shares reserved for issuance under the 2023 Plan was increased by 287,725. As of March 31, 2024, 91,516 shares were available for grant under the 2023 Plan. 2023 Employee Stock Purchase Plan The Company adopted the 2023 Employee Stock Purchase Plan (the “2023 ESPP”) which became effective at the closing of the Merger. As of the effective time of the Merger, there were 65,000 shares of the Company’s common stock reserved for issuance under the 2023 ESPP. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 ESPP of the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 195,000 shares of the Company’s common stock, or (iii) such lesser number of shares of the Company’s common stock as determined by the Company’s board of directors. An annual increase of 57,545 shares of the Company’s common stock was automatically added to the share reserve under the 2023 ESPP on January 1, 2024. As of March 31, 2024, no shares have been issued under the 2023 ESPP. The following table summarizes the stock option transactions for the 2023 Plan:
|  | Total Options |  |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at December 31, 2023 |  |  | 1,739,270 |  |  | $ |  | 15.71 |  |  |  | 6.99 |  |  | $ |  | 76 |
Granted |  |  | 595,250 |  |  |  |  | 4.16 |  |  |  | 10 |  |  |  |  | — |
Cancelled |  |  | (223,308 | ) |  |  |  | 76.63 |  |  |  | — |  |  |  |  | — |
Outstanding at March 31, 2024 |  |  | 2,111,212 |  |  | $ |  | 6.01 |  |  |  | 8.34 |  |  | $ |  | 790 |
Vested and exercisable at March 31, 2024 |  |  | 883,869 |  |  | $ |  | 7.18 |  |  |  | 6.90 |  |  | $ |  | 356 |
There were no options exercised during the three months ended March 31, 2024. The weighted-average fair value of options granted during the three months ended March 31, 2024 and 2023 was $4.16 and $11.94 per share, respectively. The total fair value of shares vested was $0.3 million for the three months ended March 31, 2024. The total fair value of shares vested as of March 31, 2023 was $10.9 million (includes $10.5 million related to the acceleration of vesting of the Graybug stock awards at the date of the Merger). As of March 31, 2024, stock-based compensation not yet recognized is $4.1 million, which the Company expects to recognize over an estimated weighted-average term of 3.0 years. The following are the underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the three months ended March 31, 2024 and 2023:
|  | Three Months Ended March 31,
|  | 2024 |  | 2023
Risk free interest rate |  | 2.94% |  | 3.56%
Expected volatility |  | 89% |  | 75%
Expected term (years) |  | 6.25 |  | 6.25
Expected dividend yield |  | 0% |  | 0%
Stock-based Compensation Expense Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):
|  | Three Months Ended March 31, |
|  | 2024 |  |  | 2023 |
Research and development |  | $ | 171 |  |  | $ | 2,080 |
General and administrative |  |  | 243 |  |  |  | 9,046 |
Total stock-based compensation expense |  | $ | 414 |  |  | $ | 11,126 |
The stock-based compensation expense for the three months ended March 31, 2023, includes one-time charges for the acceleration of vesting of the Graybug stock options at the date of the Merger of $1.9 million and $8.6 million in research and development and general and administrative expenses, respectively. Common Stock Reserved for Future Issuance Common stock reserved for future issuance consists of the following at March 31, 2024:
|  | March 31, |
|  | 2024 |
Common stock warrants |  |  | 6,026,552 |
Stock options issued and outstanding |  |  | 2,111,212 |
Shares available for issuance under the 2023 Plan |  |  | 91,516 |
Shares available under the 2023 ESPP |  |  | 122,545 |
Total |  |  | 8,351,825 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration